Summit Therapeutics PLC
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +22.2% | +31.6% | +62.6% | +4.1% | -5.1% | -0.2% | +11.6% | +544.2% | -70.3% | +116.7% | +60.2% | |
| – | +29.7% | +40.3% | +21.9% | +20.5% | +1.5% | +3.7% | +12.0% | +642.1% | -72.0% | +125.5% | +57.9% | |
| – | +36.8% | +51.1% | -18.9% | +23.8% | +41.8% | -2.4% | +9.1% | +434.0% | -80.1% | +48.2% | +99.5% | |
| – | +36.8% | +51.1% | -18.9% | +23.8% | +41.8% | -2.4% | +9.1% | +434.0% | -48.1% | +123.6% | +60.7% | |
| – | +51.5% | +107.7% | +177.6% | -4.9% | -97.5% | +2,252.1% | +70.0% | -60.8% | -86.5% | -33.7% | – | |
| – | -86.5% | -80.4% | -100.0% | – | – | -750,641,125.6% | – | +0.0% | -65.9% | – | – | |
| – | +0.0% | +39.8% | +597.4% | -23.9% | +89.4% | +9.6% | +172.4% | +45.8% | – | – | – | |
| – | -5.5% | -12.2% | +322.6% | -32.2% | -51.5% | +29.3% | -0.1% | -1.6% | +2.2% | -0.6% | -0.3% | |
| – | -5.7% | -12.3% | +382.5% | -33.5% | -44.5% | +9.6% | -8.9% | +34.9% | – | – | – | |
| – | -42.1% | +814.4% | +21.5% | -62.0% | -39.6% | +18.0% | +31.8% | +1,864.5% | -77.4% | -62.3% | +83.2% | |
| – | -15.1% | +198.3% | +96.9% | -36.0% | -42.4% | +47.6% | +30.0% | +66.4% | -48.9% | +106.5% | +62.4% | |
| – | – | 0.0% | +254.0% | -100.0% | – | – | +182.3% | +2,063.1% | -87.3% | +35.3% | -16.4% | |
| – | -15.1% | +9.1% | +153.9% | -54.1% | -41.8% | +33.6% | -28.1% | -91.1% | +629.3% | +75.5% | +306.5% | |
| – | – | – | – | – | – | – | – | – | -79.8% | – | – | |
| – | +54.1% | -114.5% | – | +299.1% | +9.5% | -4.5% | +5.8% | +67.2% | -40.5% | +405.3% | +57.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +49.3% | +4.1% | +6.3% | +31.7% | -61.9% | +111.8% | +32.7% | +109.6% | +220.5% | +16.0% | +4.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.